These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18307687)

  • 1. Chemotherapy in hormone-refractory prostate cancer.
    de Wit R
    BJU Int; 2008 Mar; 101 Suppl 2():11-5. PubMed ID: 18307687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    Nayyar R; Sharma N; Gupta NP
    Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
    Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
    Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
    Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
    Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
    Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
    Berthold DR; Pond GR; Soban F; de Wit R; Eisenberger M; Tannock IF
    J Clin Oncol; 2008 Jan; 26(2):242-5. PubMed ID: 18182665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
    Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
    J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
    Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    Sella A; Sternberg C; Kovel S; Yarom N; Skoneczna I
    BJU Int; 2007 Sep; 100(3):533-5. PubMed ID: 17559560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.